A new clinically proven and reliable medical solution for continuous heart arrhythmia and blood pressure monitoring

Información del proyecto

CARDIACSENSE

Identificador del acuerdo de subvención: 836167

DOI

10.3030/836167

Proyecto cerrado

Fecha de la firma de la CE 7 Diciembre 2018

Fecha de inicio 1 Diciembre 2018

Fecha de finalización 31 Marzo 2019

Financiado con arreglo a

• INDUSTRIAL LEADERSHIP - Innovation In SMEs

Coste total

€ 71 429,00

Aportación de la UE

€ 50 000,00

Coordinado por

CARDIACSENSE
Israel

Periodic Reporting for period 1 - CARDIACSENSE (A new clinically proven and reliable medical solution for continuous heart arrhythmia and blood pressure monitoring)

Período documentado: 2018-12-01 hasta 2019-03-31

Resumen del contexto y de los objetivos generales del proyecto

Almost 40% of adults suffer from hypertension (HTN) worldwide; a condition that can lead to heart attacks, ischemic heart disease and strokes. Likewise, 2,9% of the global population suffers from Atrial Fibrillation (AF), which may likewise lead to strokes, debility and death. It is estimated that the global extrapolated cost of AF is approximately €500 billion annually. Monitoring blood-pressure and heart-rate can cut the rate of heart-failure in patients by 33%. Monitoring is done on-site at clinics, placing a time and cost burden on these facilities that remote monitoring could prevent. Remote monitoring necessitates a clinical-grade monitoring system, however. CS Ltd has developed a clinically-proven, remote cardiac monitoring wearable that is comfortable, easy to use and allows long term continuous monitoring of all markers essential for management of conditions like AF and HTN. Worn as a watch that interacts with an app on the doctor’s and patient’s mobile phones, our technology is affordable and simple. It is the only technology capable of eliminating all movement artefacts, making it the most accurate method of heart-rhythm monitoring worldwide. Our device stands to save around €800M to EU healthcare and save up to 5000 lives yearly, by relieving the burden of monitoring visits and reducing the risk of heart attacks and strokes.

Trabajo realizado desde el comienzo del proyecto hasta el final del período abarcado por el informe y los principales resultados hasta la fecha

To date, CS Ltd has produced an alpha prototype of their innovation. During the study period, we refined the prototype and performed clinical trials, testing our device on a variety of skin-types and tissue depths and comparing it to the current predicate (ECG). These trials show sensitivity of 99% and false-detection-rate of below 1%. We have begun to establish links to distribution and production partners, refined our business plan, identified competitors and made a full risk analysis. We have performed a thorough FTO analysis and secured additional funding. We stand at TRL7.

Avances que van más allá del estado de la técnica e impacto potencial esperado (incluida la repercusión socioeconómica y las implicaciones sociales más amplias del proyecto hasta la fecha)

CS Ltd produce a clinical-grade wearable monitoring device (watch) based on PPG (photoplesythmography), a technique that monitors the fluid motion in patient blood-vessels by monitoring how visible (LED) light reflects from them. This is different to other clinical-grade monitoring devices, which are based on electrocardiogram (ECG/EKG) technology and must therefore be worn on the chest or implanted. Unlike “consumer grade” wearables and smartwatches (such as the Apple Watch), CardiacSense is a medical-grade wearable: it can provide continuous monitoring at the level of accuracy required for detecting arrythmias like AF. A major drawback to PPG is “motion artefacts” that happen when a wearer moves their hand. We are the only company worldwide to develop a PPG sensor that eliminates all motion artefacts. This makes us the only device with enough sensitivity to accurately signal the onset of heart arrhythmias (such as Atrial Fibrillation and Cardiac Arrest).

image-1.png